- ￥346 - 3880
- Solarbio
- 北京
- IN0920
- 2026年01月29日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 保质期：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 英文名：
Nazartinib
- 库存：
现询
- 供应商：
北京索莱宝科技有限公司
- CAS号：
1508250-71-2
- 规格：
50mg/25mg/10mg/5mg/1mg
| 规格： | 50mg | 产品价格： | ￥3880.0 |
|---|---|---|---|
| 规格： | 25mg | 产品价格： | ￥2460.0 |
| 规格： | 10mg | 产品价格： | ￥1370.0 |
| 规格： | 5mg | 产品价格： | ￥824.0 |
| 规格： | 1mg | 产品价格： | ￥346.0 |
一种新型，共价/不可逆的突变体选择性EGFR抑制剂。
| 基本信息 | |
| CAS | No.1508250-71-2 |
| 中文名称 | 那扎替尼 |
| 英文名称 | Nazartinib |
| 别名 | ;EGF816;EGF-816; |
| 分子式 | C26H31ClN6O2 |
| 分子量 | 495.02 |
| 溶解性 | Soluble in DMSO |
| 纯度 | ≥98% |
| 外观(性状) | Off-white to yellow Solid |
| 储存条件 | Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year |
| MDL | MFCD28963918 |
| SMILES | O=C(C1=CC(C)=NC=C1)NC2=NC3=CC=CC(Cl)=C3N2[C@H]4CN(C(/C=C/CN(C)C)=O)CCCC4 |
| 靶点 | EGFR |
| 通路 | Angiogenesis;Protein Tyrosine Kinase/RTK; JAK/STAT Signaling |
| 背景说明 | 一种新型,共价/不可逆的突变体选择性EGFR抑制剂。 |
| 生物活性 | Nazartinib (EGF816) is a covalent mutant-selective EGFR inhibitor， with Ki and Kinact of 31 nM and 0.222 min?1 on EGFR(L858R/790M) mutant， respectively[1-2] |
| In Vitro | Nazartinib (EGF816) has inhibitory effect on the mutant cell lines with IC50s of 4， 6， 2 nM in H1975， H3255， and HCC827， respectively， and demonstrates improved ADME and PK properties[1]. Nazartinib (EGF816) shows potent inhibition of pEGFR levels in H3255， HCC827， and H1975 cell lines with EC50 values of 5， 1， and 3 nM， respectively. Nazartinib inhibits cell proliferation， with EC50 values of 9， 11， and 25 nM in H3255， HCC827， and H1975， respectively. Nazartinib has an OC50 (compound concentration at 50% occupancy) value of 2 and 5 nM on HCC827 and H1975， respectively[2]. |
| 细胞实验 | In H1975 mouse xenograft model， Nazartinib (EGF816; 50 and 20 mg/kg or 25 mg/kg， p.o.) demonstrates dose-dependent efficacy with near complete tumor cells regression at the highest dose tested (50 mg/kg)[1]. In H1975 mouse model， Nazartinib (EGF816; 10 mg/kg， p.o.) induces tumor growth inhibition with a T/C (tumor/control volume) of 29%， and when doses are 30 and 100 mg/kg， tumor regressions are achieved (T/C， -61% and -80%， respectively). In the H3255 xenograft model， Nazartinib (30 mg/kg， p.o.) shows significant antitumor activity. Antiproliferative activity of Nazartinib on 89 lung cancer cell lines indicates that Nazartinib selectively inhibits cell lines containing EGFR with catalytic domain mutations[2]. |
| 细胞实验 | Cells are seeded 500 cells/well in solid white 384-well plates in maintenance media. Serial diluted compounds are transferred to cells. After 3 days， cell viability is measured by CellTiter-Glo. BaF3 cell viability is measured 2 days after compound treatment using Bright-Glo Luciferase Assay System. Luminescent readout is normalized to 0.1% DMSO-treated cells and empty wells. Five EGFR TKI-resistant cell lines are generated at Massachusetts General Hospital. MGH134， MGH121， MGH141， and MGH157 are derived from patients who developed resistance to erlotinib with acquired T790M mutation. MGH119-R is generated in vitro by treating MGH119 with gefitinib for a prolonged period. The sensitivity of Nazartinib on these lines is tested.[1-2] |
| 动物实验 | Foxn1 nude mice bearing the H1975 tumors are randomized and used for efficacy studies. Compounds are formulated in 0.5% MC， 0.5% Tween 80 suspension formulation and administered by oral gavage at a dosing volume of 10 μL/g of the animal body weight. Animals in each group receive one oral dose of either vehicle (n=6) or the different test compounds (n=6 in each dose group). Plasma samples are collected for PK measurements at 30 min， 3 h， 7 h， and 24 h after last dose on day 5. Body weight is monitored daily， and the % change in body weight is calculated as [(BWcurrent-BWinitial)/(BWinitial)]×100. Data are presented as percent body weight change from the day of treatment initiation. Tumor sizes are assessed three times during the efficacy study for 5 days. Tumor sizes are determined by using caliper measurements. Tumor volumes are calculated with the formula (length×width×width)/2.[1-2] |
| 激酶实验 | Recombinant kinase domain of EGFR L858R and T790M-L858R mutants are incubated with Nazartinib to confirm covalent modification of EGFR and site of adduction. Recombinant enzyme is incubated at room temperature with a 20-fold molar excess of compound in 40 mM Tris， pH 8， 500 mM NaCl， 1% glycerol， 5 mM TCEP for 1 h. The reaction is quenched by addition of dithiothreitol (DTT， 80-fold excess to compound) and transfer to ice. A third of the reaction (10 μL) is processed for intact MS by adding an equal volume of 6 M Guan HCl， 100 mM Tris， pH 8， 20 mM DTT， 10 mM TCEP and incubating at room temperature for 15 min. Intact MS analysis is performed on an Agilent 6520 QToF mass spectrometer equipped with a dual spray ion source (IS of 4500 V， fragmentor of 250 V， fas temp of 350°C， and skimmer of 75 V). The samples are injected onto a PLRP-S column (2.1 mm×50 mm)， heated to 60°C， and desalted for 2 min at 500 μL/min and 3% B prior to elution with a fast gradient of 3-50% B in 3 min (B， 0.1% formic acid). The data are analyzed in MassHunter for automatic peak selection， integration， and spectral deconvolution with a mass range of 15?000-75?000 Da.[1-2] |
| 数据来源文献 | [1]. Lelais G， et al. Discovery of (R，E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816)， a Novel， Potent， and WT Sparing Covalent Inhibitor of Oncogenic (L858R， ex19del) and Resistant (T79 [2]. Jia Y， et al. EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor. Cancer Res. 2016 Mar 15;76(6):1591-602 |
| 单位 | 瓶 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验相关实验
glioma. 科学问题：利用蛋白质组学方法探讨表皮生长因子 -EGFR- 血管生成轴在胶质瘤发生中的作用，并探讨司美替尼对胶质瘤的治疗效果。 研究内容 蛋白质组分析：对 10 例 EGFR 阳性和 10 例 EGFR 阴性胶质瘤病例的肿瘤组织样本进行蛋白质组分析。蛋白质组学发现 EGFL7 在 EGFR 阳性的胶质瘤组织高表达，利用公共数据库的全基因组测序数据，对 EGFL7 表达量进行验证，并与预后关联。 细胞水平上：特异性敲除了 U87-MG 和 U251-MG 细胞中的 EGFL7。免疫
不同基因类型的病人，设计合理的治疗方案；增加药物的特异性和安全性，最大限度地优化治疗等意义。分子病理在肺癌个性化治疗中的新应用 新的治疗靶标如c-MET、ROS1不断涌现。中山大学肿瘤医院分子诊断科邵建永教授讲到，在肺癌的个性化治疗中，分子检测可以指导化疗与靶向药物的敏感性，如筛选对靶向EGFR药物EGFR-TKI敏感的患者；筛选靶向ALK-EML4基因融合药物克唑替尼敏感性的患者。同样其对靶向药物耐药性有指导作用，如检测EGFR T790M突变可以指导TKIs耐药性。肺癌新驱动基因
Cell Metab：季彤/王旭/孙树洋发现癌痛调控肿瘤发展新机制
境启动了肿瘤细胞与伤害性感觉神经间的交互调控。 最后，以这些分子机理为基础，作者们发现：抗糖酵解治疗（2-DG、氯尼达明）和抗血管生成治疗（安罗替尼、贝伐珠单抗）这两类肿瘤饥饿疗法，都能显著增强肿瘤细胞-伤害性感觉神经间的交互作用，而使用一类国内外均已上市的偏头痛治疗药物—CGRP 受体拮抗剂以阻断伤害性感觉神经来源的 CGRP 作用，可以显著增强肿瘤饥饿治疗的疗效。 总之，此研究表明肿瘤细胞在营养匮乏时，可以主动「劫持」伤害性感觉神经合成与分泌 CGRP，从而促进自身细胞保护性自噬。而使用一种
技术资料暂无技术资料 索取技术资料
IN0920 那扎替尼 血管生成 索莱宝
￥346 - 3880
